Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02640066
Other study ID # 117-15-ZIV
Secondary ID
Status Recruiting
Phase N/A
First received December 22, 2015
Last updated June 8, 2016
Start date June 2016
Est. completion date February 2018

Study information

Verified date June 2016
Source Ziv Hospital
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Interventional

Clinical Trial Summary

Acute viral respiratory infections are among the most common causes of hospitalization in the pediatric population. The usual presentation of viral respiratory tract infections (VRTI) includes fever, malaise, wheezing and or coughing, rhinorrhea and loss of appetite. Up to 50% of children will have at least one viral-induced wheezing illness by school age. Currently treatment of VRTI is essentially supportive and no specific and efficient treatments are known. Given the lack of effective medications, current treatment for severe viral lower respiratory tract infection (LRTI) in infants relies on supportive measures only. These measures include supplementation of oxygen, monitoring of apnea, nasal/gastric tube feeding or intravenous fluids, and, if required, respiratory support with nasal bi-level positive-airway pressure. VTRI therefore represent an important unmet need for improved treatment strategies. Acupuncture's effect on has also been studied. Acupuncture has been shown to be a safe and effective in various respiratory tract inflammations. A review published in 2011 have found that acupuncture is safe for pediatric patients. Acupuncture's effect on acute viral induced wheezing and cough in hospitalized children has yet to be studied. Since the current standard of care is supportive care only, using acupuncture as an additional treatment may provide benefit in reducing wheezing, respiratory distress, and shorten hospitalization.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date February 2018
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender Both
Age group 3 Months to 36 Months
Eligibility Inclusion Criteria:

- The presence of acute viral respiratory disease

Exclusion Criteria:

- Evidence of chronic cardio-pulmonary disease, immune-suppression or any chronic systemic disease or disability

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
acupuncture


Locations

Country Name City State
Israel Ziv Medical Center Zefat

Sponsors (1)

Lead Sponsor Collaborator
Ziv Hospital

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary presence of fever 5 days No
Primary presence of cough 5 days No
Primary presence of rhinitis 5 days No
Primary symptoms of pharyngitis 5 days No
Primary presence of crepitations 5 days No
Primary presence of dyspnea or tachypnea respiratory rate 5 days No
Primary oxygen saturation measured by (SpO2) 5 days No
See also
  Status Clinical Trial Phase
Terminated NCT04815018 - Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2
Completed NCT05093530 - Safety and Tolerability of Single and Multiple Doses of Neumifil Phase 1
Recruiting NCT06248983 - Transmission Of Respiratory Tract microOrganisms In a School Environment
Completed NCT05290792 - Use of Wearable Sensors for Early Detection and Tracking of Viral Respiratory Tract Infections N/A